| Literature DB >> 33555451 |
Walid El Ansari1,2,3, Wahiba Elhag4.
Abstract
Some patients experience weight regain (WR) or insufficient weight loss (IWL) after bariatric surgery (BS). We undertook a scoping review of WR and IWL after BS. We searched electronic databases for studies addressing the definitions, prevalence, mechanisms, clinical significance, preoperative predictors, and preventive and treatment approaches including behavioral, pharmacological, and surgical management strategies of WR and IWL. Many definitions exist for WR, less so for IWL, resulting in inconsistencies in the reported prevalence of these two conditions. Mechanisms and preoperative predictors contributing to WR are complex and multifactorial. A range of the current knowledge gaps are identified and questions that need to be addressed are outlined. Therefore, there is an urgent need to address these knowledge gaps for a better evidence base that would guide patient counseling, selection, and lead to improved outcomes.Entities:
Keywords: Bariatric surgery; Definitions; Insufficient weight loss; Management; Mechanisms; Predictors; Prevention; Weight regain
Mesh:
Year: 2021 PMID: 33555451 PMCID: PMC8012333 DOI: 10.1007/s11695-020-05160-5
Source DB: PubMed Journal: Obes Surg ISSN: 0960-8923 Impact factor: 4.129
Selected examples of definitions and prevalence of WR and IWL after BS
| Characteristic | Unit/component/s | Examples |
|---|---|---|
| Definition | ||
| WR | Using EWL% | > 25% EWL from nadir [ |
| Using nadir weight % | ≥ 10% [ | |
| Using nadir weight kg | ≥ 10 kg from nadir [ | |
| Using maximum WL | ≥ 10% [ | |
| Using pre-surgery weight | ≥ 10% WR of pre-surgery weight [ | |
| Using any WR after remission | Any WR after T2DM remission [ | |
| Using any WR | Any WR [ | |
| Using BMI | ≥ 5 BMI kg/m2 points from nadir [ | |
| Increase in BMI > 35 kg/m2 after successful WL [ | ||
| IWL | Using EWL% | EWL of < 50% at 18 months [ |
| Prevalencea | ||
| WR | Post-LAGB (38%) [ | |
| IWL | After LSG (32–40%) [ | |
Range of definitions and prevalence selected are examples for illustration purposes only and do not include all examples in the literature. EWL excess weight loss, WR weight regain, IWL insufficient weight loss, WL weight loss, T2DM type 2 diabetes, BMI body mass index, LAGB laparoscopic adjustable gastric banding, LSG laparoscopic sleeve gastrectomy, OAGB one anastomosis gastric bypass
aPrevalence of WR are different depending on choice of BS procedure, varied assessment methods (EWL, weight from Nadir), and various follow-up periods
Summary of causes, predictors, and prevention and management strategies of WR and IWL after BS
| Characteristic | Summary |
|---|---|
| Causes | |
| Hormonal/metabolic | Increase in ghrelin, decrease in peptide YY and GLP-1, post-bariatric hypoglycemia, role of leptin is unclear [ |
| Dietary non-adherence | Increase caloric intake with time, dietary non-adherence/food indiscretion, grazing, lack of nutritional follow-up [ |
| Physical inactivity | Non-compliance, sedentary behavior, presence of barriers to exercise [ |
| Mental health | Depression, multiple psychiatric conditions, binge eating disorder, loss of control over eating [ |
| Anatomic surgical failure | |
| LAGB | Pouch distension [ |
| LSG | Dilatation of gastric pouch [ |
| RYGB | Dilatation of gastric pouch, dilatation of gastrojejunostomy stoma outlet, gastrogastric fistula [ |
| Predictors | Older age, male gender, higher preoperative BMI, mental health issues, presence of comorbidities (T2DM, hypertension, OSA) [ |
| Prevention and management | |
| Behavioral | Cognitive behavioral therapy, remote acceptance-based behavioral intervention, lifestyle counseling [ |
| Dietary | Counseling with dietitian, structured dietary intervention [ |
| Pharmacological | FDA approved: phentermine, phentermine–topiramate extended release, liraglutide, bupropion/naltrexone |
| Off label: metformin, topiramate, zonisamide, bupropion [ | |
| Surgical (management only) | |
| After failed LAGB | Conversion to LSG, RYGB, BPD/DS [ |
| After failed LSG | Conversion to RYGB, BPD/DS [ |
| After failed RYGB | Conversion to DRYGB or to BPD/DS; or revision of gastric pouch and anastomosis, revision with gastric band [ |
WR weight regain, IWL insufficient weight loss, BS bariatric surgery, GLP-1 glucagon-like protein-1, LAGB laparoscopic adjustable gastric banding, LSG laparoscopic sleeve gastrectomy, RYGB Roux-en-Y gastric bypass, BPD/DS biliopancreatic diversion with duodenal switch, FDA Food and Drug Administration, DRYGB distal RYGB
IWL and WR after BS: area and extent of current knowledge gaps
| Knowledge gap | Extent of gapa | Summary of potential gap | |
|---|---|---|---|
| WR | IWL | ||
| Inconsistent reporting | + + | + + + + | Small sample sizes, patient recall to estimate nadir weight, loss to follow-up, and variability of follow-up times [ |
| Lack of standardization | + + + | NA | Varied definitions, consensus statements, and guidelines of WR [ |
| Clinical significance | + + | Relationships between different WR definitions and clinical outcomes require to be established [ | |
| + + + + | No data on clinical significance of IWL, urgently needed | ||
| Limited data on | |||
| Prevalence | + | Prevalence data mostly on WR [ | |
| + + + | Sparse data on prevalence of IWL [ | ||
| Mechanism/s | + + + | Small studies on WR | |
| + + + + | Very sparse data on mechanism/s of IWL | ||
| Gut hormones | + + + | Ghrelin, GLP, GIP: sparse data, small sample sizes; no long-term evidence [ | |
| + + + + | Very few studies on gut hormones, leptin or PBH in relation to IWL | ||
| Dietary non-adherence | + + + | Few small-sized prospective studies, more RCTs required [ | |
| + + + + | Virtually no prospective studies on associations of caloric intake, macronutrient composition, dietary non-adherence, and food indiscretion with IWL | ||
| Physical in/activity | + + + | Difficult to assess due to discrepancy between self-reported and measured PA [ | |
| + + + + | Very sparse data on PA types, durations and levels, and their associations with IWL | ||
| Mental health | + + + | Relationship between preoperative depression and WR is unclear; research is required to establish the direction of the relationship [ | |
| + + + + | Few reports on number of psychiatric diseases and loss of control over eating in relation to IWL [ | ||
| Surgical | + | Most studies on WR [ | |
| + + + + | Role of surgical causes in IWL practically not assessed | ||
| Management | |||
| Behavioral | + + + | Small studies with short follow-up in WR, no RTCs [ | |
| + + + + | No prospective studies of patients with IWL | ||
| Dietary | + + + | WR: few studies with small sample sizes and short durations (education sessions, structured dietary intervention); long-term, larger RCTs are needed [ | |
| + + + + | No published data available on effects of dietary management in IWL | ||
| Pharmacological | + + + | Small-sized retrospective observational studies, short follow-ups [ | |
| + + + + | Effects of pharmacological therapy for IWL usually assessed in combination with WR [ | ||
| Surgical revision | + | Effects of surgical revision on weight usually assess WR and IWL combined [ | |
| + + + + | No RCTs of the effects of various revisional surgeries on IWL (for failed LAGB, LSG, RYGB) [ | ||
WL weight loss, WR weight regain, IWL insufficient weight loss, RCT randomized controlled trials, PYY peptide YY, NA not applicable, PBH post-bariatric hypoglycemia, PA physical activity
aThe number of (+) signs signifies the extent of the current knowledge gap, where (+) suggests a small gap, while (+ + + +) indicates a large gap in the current available knowledge
IWL and WR after BS: Research questions to enhance the evidence base
| Topic area | Example |
|---|---|
| Defining the concept | Unit/s: What unit/s should be used to define WR/IWL? (e.g., nadir weight? EWL%?, kg?) |
| Cutoff: Is there controlled (or acceptable) WR/IWL (e.g., 20–50 %WR from nadir after 2 years) and significant (or non-acceptable) WR/IWL? | |
| Definition: What is an appropriate definition of significant WR/IWL post-BS? | |
| Components: Should the appropriate definition be based solely on WR per se, or should it also incorporate element/s of the clinical implication/s resulting from WR/IWL? (e.g., recurrence of T2DM, HTN, dyslipidemia, deteriorated QoL?) | |
| Prevalence | Based on the above, what is a “true” prevalence of WR/IWL after different types of BS? |
| Separation: As WR and IWL have distinct definitions, should they be reported collectively or separately in future studies? | |
| Mandatory reporting: Should WR/IWL be one of the standard WL outcomes in comparisons of short-, medium-, and long-term outcomes of different types of BS? | |
| Clinical outcomes | Generalization: Do WR/IWL always lead to recurrence of comorbidities? (e.g., why not all patients with WR experience recurrence of T2DM?) |
| Extent: What are the impact/s of WR/IWL on changes in the status of different comorbidities? | |
| Patient/s: Is the extent of such impact/s different among patients (e.g., individualized to each patient)? | |
| Comorbidity/ities: Does the recurrence of a particular comorbidity/ities (e.g., T2DM, HTN, dyslipidemia, OSA) represent a sensitive “indicator” of the impact of WR/IWL? | |
| Predictors | Known: Does addressing known pre-op predictors prevent WR/IWL or change their clinical outcomes? (e.g., lower BMI, younger age, earlier surgery)? |
| Unknown: Are there additional modifiable/non-modifiable pre-op predictors of WR/IWL than already known (e.g., ghrelin, leptin)? | |
| Selection: Should such predictors guide the selection of the type of BS (e.g., malabsorptive surgery for higher BMI or patients with comorbidities such as T2DM)? | |
| Mechanisms | Hormones: What is the precise role/s of various hormones (GLP-1, PPY, leptin) in WR and in IWL? |
| Mental Health: What are the effect/s of maladaptive eating on WR/IWL (e.g., grazing, binge eating)? | |
| Psychiatric conditions: How do pre- and postop psychiatric illness affect WR/IWL (relationship/e.g., direction of depression and WR)? | |
| Physical activity: What is the precise role of PA in WR/IWL? How can PA be accurately assessed (e.g., discrepancy between objectively/subjectively measured PA) | |
| Surgery: How can the primary surgical technique be improved to prevent WR/IWL (e.g., biliopancreatic limb length)? | |
| Others: Are there other mechanisms that contribute to WR/IWL (e.g., exact role/s of gut microbiomes, bile acids)? | |
| Management | |
| Behavioral | Type and mode: What is the effectiveness of various types/modes of delivery of behavioral therapies (e.g., group vs individualized, face to face vs remote)? |
| Timing: When should behavioral therapy be introduced to effectively prevent or treat WR/IWL (e.g., preventive at weight plateau vs management after WR)? | |
| Pharmacological | Type and dose: What is the effectiveness of various medication to manage WR/IWL (e.g., type of medication, single vs combination, effective dose)? Timing: What is the optimal time for medication/s to be introduced (e.g., preventive at weight plateau vs management after WR)? |
| Surgical | Revision type: What is the suitable type of revisional surgery for WR/IWL (e.g., better WL outcomes and lower complications)? |
WL weight loss, WR weight regain, IWL insufficient weight loss, WL weight loss, EWL% excess weight loss percentage, T2DM type 2 diabetes, HTN hypertension, OSA obstructive sleep apnea, GLP-1 glucagon-like protein-1, PPY peptide YY, PA physical activity, QoL quality of life, pre-op preoperative, BS bariatric surgery, PA physical activity